Furthermore, the results of a recently completed confirmatory French RCT for GM-CSF treatment of sepsis patients with low mHLA-DR will finally evaluate the value of HLA-DR as a theranostic marker for immunotherapy (ClinicalTrials.gov identifier NCT02361528). Here, CSF2 is linked to Sepsis.